Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Moyamoya disease (MMD) is a rare intracranial arteriopathy involving progressive stenosis of the cerebral vasculature located at the base of the brain causing transient ischemic attacks or strokes.
Biomarker and diagnostic research for Moyamoya disease has been reported in the published literature.
Estimated prevalence: 1-9 in 1,000,000 (Rare).
27 clinical trials registered, 18 recruiting. Interventions under study include other interventions, medical devices, drug therapy, and procedural interventions. Pipeline includes 2 PHASE1, 9 NA. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06817434](https://clinicaltrials.gov/study/NCT06817434) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 1:02 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Moyamoya disease
Study on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya Disease |
— |
Beijing Tiantan Hospital |
RECRUITING |
[NCT05332756](https://clinicaltrials.gov/study/NCT05332756) | Long-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA) | — | Beijing Tiantan Hospital | RECRUITING |
[NCT05961748](https://clinicaltrials.gov/study/NCT05961748) | Registry of Multicenter Brain-Heart Comorbidity in China | — | Beijing Tiantan Hospital | RECRUITING |
[NCT06832839](https://clinicaltrials.gov/study/NCT06832839) | Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease | — | Beijing Tiantan Hospital | RECRUITING |
[NCT03546309](https://clinicaltrials.gov/study/NCT03546309) | Safety and Efficacy of RIC in Pediatric Moyamoya Disease Patients Treated With Revascularization Therapy | NA | Capital Medical University | RECRUITING |
395 publications have been identified in PubMed for Moyamoya disease. Research spans Review / Meta-Analysis (22%), Basic Science / Preclinical (16%), and Epidemiology / Natural History (16%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 86 | 22% |
Laboratory research | 65 | 16% |
Disease patterns and progression | 64 | 16% |
Patient case studies | 63 | 16% |
Clinical study results | 56 | 14% |
Testing and diagnosis research | 43 | 11% |
New treatment approaches | 11 | 3% |
Other research | 7 | 2% |
Patel R (2026). [PMID: 41355354](https://pubmed.ncbi.nlm.nih.gov/41355354/). *Current opinion in neurology*. [Review / Meta-Analysis]
Lopes C (2026). [PMID: 41825070](https://pubmed.ncbi.nlm.nih.gov/41825070/). *J Neurosurg Pediatr*. [Case Report / Case Series]
Das S (2026). [PMID: 41793513](https://pubmed.ncbi.nlm.nih.gov/41793513/). *Childs Nerv Syst*. [Basic Science / Preclinical]
Zrelak PA (2026). [PMID: 42103421](https://pubmed.ncbi.nlm.nih.gov/42103421/). *Crit Care Nurs Clin North Am*. [Review / Meta-Analysis]
Cuccurullo C (2026). [PMID: 41557218](https://pubmed.ncbi.nlm.nih.gov/41557218/). *Neurol Sci*. [Case Report / Case Series]
Santoro JD (2026). [PMID: 42495733](https://pubmed.ncbi.nlm.nih.gov/42495733/). *Stroke*. [Case Report / Case Series]
Birkeland P (2026). [PMID: 41738502](https://pubmed.ncbi.nlm.nih.gov/41738502/). *Br J Neurosurg*. [Review / Meta-Analysis]
Lin J (2026). [PMID: 42069998](https://pubmed.ncbi.nlm.nih.gov/42069998/). *Acta Neurochir (Wien)*. [Case Report / Case Series]
Zhao M (2026). [PMID: 41769189](https://pubmed.ncbi.nlm.nih.gov/41769189/). *Biomed Rep*. [Basic Science / Preclinical]
Shi X (2026). [PMID: 41871431](https://pubmed.ncbi.nlm.nih.gov/41871431/). *J Neurosurg*. [Diagnostic / Biomarker]
AI-curated news mentioning Moyamoya disease
Updated Sep 18, 2026
A recent meta-regression study explores the prediction of cerebral hyperperfusion syndrome following STA-MCA bypass in patients with moyamoya disease using CT perfusion techniques. This research could enhance surgical outcomes and patient management strategies.
A systematic review highlights cognitive deficits in patients with non-revascularized moyamoya disease, emphasizing the need for neuropsychological assessments. This research provides insights into the cognitive challenges faced by this patient population.
A case report details an unusual presentation of moyamoya disease managed conservatively in a resource-limited region. This study contributes to the understanding of the disease's variability and management options.